Approximately 90% of 3-mo-old and 100% of 7-and 12-mlo-old infants had detectable antibody responses to primary immunization with C vaccine. The 100-iug dose appeared to be optimal, resulting in geometric mean anti-C concentrations of 0.49, 1.55, and 2.64 Mug/iln in 3-, 7-, and 12-mo-old infants, respectively. Significalnt booster responses were not observed with C vaccine. Indeed, except for the 10-,ug dose, booster injections of C vaccine in 7-and 12-mo-old ilnfants resulted in lower anti-C concentrations than did primary immunizations.
IN'TRIODUCT ION .\Meiiimmgococcal disease is a inajor catuse of mortality aii(l morbidity amioing chlildreni tlhi-ouglhout the wN-orld. The RccCived for publication 21 MaJurch l,1J S1nd(1 il ri'vis.-(l fornm 4 August 1975. peak incidence in the United States occurs in infants 4-6 mo of age (1) . Uncder endemic con(litions, 50% of cases occur in children under 2, 10% in childrein 2-4, and 10%c in clhildren 5-9 yr of age (1) (2) (3) . During epi-(lemlics, there is a shift in the age (listribution so that 20%; of cases occur in clild(l-eni under 2 and mlore thanl 50% in clildren 2-14 yr of age (4 (5) . Mlost mlajor outbreaks of imieninigococcal disease (luring the past 10 yr have been caused by sulfonamiiideresistanit strains of meningococci.
Vaccines, consistincg of highly purified group A and group C meningococcal capsular polvsacchlarides, were developed at the \Valter Reed Army Institute of Researclh (6) and(I halve und(lergonie extensive evaluation. Tlle groui) C vaccine lhais been showN-n to be safe andl effective in U. S. Army recruits (7, 8) . Field trials underway in Sao Paulo, Brazil, inidicate that the group C vaccine provides signlificant protectioni against disease in children over 2 yr of age (9) . The efficacy of the group A vaccine in preveniting disease has been demonstratedI in Egyptian school children (10) and in a mlixed-age population in the Sudan (11) .
Relatively little is known about the safety, imimilluIngenicity, and efficacy of the meninigococcal polysacclharide vaccines in infants. Preliminary studies Nith smlall numiibers of infanits have indicated that their antibody responises to the -accinies are significanitly lower tlhan those of older clildren (12) (13) (14) (15) (16) .
The l)resent study las anti-C, antibody to C vaccine.
Reed Army Institute of Research, Washington, D. C., and lot A-7, prepared by E. R. Squibb & Sons, Princeton, N. J. The molecular weights of lot A-5 and lot A-7 were 85,000 and 47,000, respectively (13) . The group C meningococcal polysaccharide C vaccine (lot C-10) was prepared by E. R. Squibb & Sons. All lots had been tested in adults and older children before use in infants. The vaccines, lyophilized in 0.9%o NaCl and stored at -20°C, were reconstituted with pyrogen-free water to a concentration of 100 4g/ml. Additional dilution to a concentration of 50 ,ug/ml was made with 0.9% NaCl for use in infants receiving a dose of 5 ,ug. VTaccine was administered subcutaneously with needle and syringe into the deltoid region of the arm.
Schedu(le of i)mnmuivationz. The ages of the infants at the times of immunization were: 2.8±1.0; 7.0±1.1, and 11.5 ±+1.0 mo (mean+2 SD). The schedule of immunizations outlined in Table I was designed with several goals in mind: (a) to analyze the dose response of 3-mo-old infants to each vaccine over a dose range of 5-200 ,ug; (b) to determine the effect of age upon the response to primary immunization at 3, 7, and 12 mo of age; (c) to determine whether immunization at 3 mo of age leads to an anamnestic response at 7 or 12 mo of age; (d) to determine the effect of A vaccine on subsequent immunization with C vaccine and vice versa; and (e) to compare the response to two lots of A vaccine. infants at every visit and sufficient quantities of each serum were not always available for testing against both A and C polysaccharides. However, all available sera were tested. The number of infants from whom sera were not available for testing are indicated in each of the tables giving the results of the antibody assays. Serum was separated and stored in 1-ml portions at -70°C. All sera were analyzed by the radioactive antigen binding test previously described (13, 17) . Results of the anti5ody responses to immunization with A and C vaccine are expressed in two ways: as the geometric mean antibody concentrations ( micrograms of antibody protein per milligram of serum ) of each group of infants before and 1 mo after immunization, and as the seroconversion rate. Sera that had undetectable levels of anti-A or anti-C were assigned the lower limits of the antibody assay, namely 0.13 and 0.10 Ag/ml, when calculating the geometric means. A seroconversion was defined as a change from nondetectable (less than 0.10 jug/ml for anti-C and less than 0.13 ,ug/ml for anti-A) to detectable concentrations, or a two-fold increase in detectable antibody protein concentration.
Bacteriological methods. High posterior pharyngeal swabs were obtained at each visit and plated on ThayerMartin medium. Isolates were identified as Neisseria mentingitidis and serogrouped by standard methods (18) . No group A or C strains were recovered from any infants. Details of the carrier data will be the subject of a separate communication.
Reaction surveillance. Cross-reactivity of A and C vaccines. The heterologous antibody responses of 12-mo-old infants receiving primary or booster immunization with A or C vaccine are given in Table III . No significant differences between pre-and postimmunization geometric mean antibody concentrations were observed. Similar lack of cross-reactivity of the A and C vaccine was seen after immunization of infants at 3 and 7 mo of age.
Antibody response to A vaccine Natural acquisition of anti-A. At 3 mo of age, 60% of infants had detectable antibodies to the A polysaccharide, resulting in a geometric mean anti-A concentration of 0.36 4g/ml (Table IV) . The anti-A concentration decreased to 0.20 /g/ml by 7 mo of age and ranged between 0.17 and 0.30 ug/ml at 12 mo of age.
Response to primary immunization. The response of infants to primary immunization with A vaccine at 3, 7, (Table V: x= 99.81, P < 0.001). In 7-mo-old infants, the seroconversion rates of immunized infants were significantly higher than that of the control infants (x2 = 11.21, P < 0.001).
As illustrated in Fig. 1 (Table IV) . Seroconversion rates were also higher at 12 than at 7 mo of age, although the differences were not statistically significant (Table V: x' = 3.029, P > 0.05). At 3, 7, and 12 mo of age the dose-response curves were flat. There were no significant differences between the postimmunization geometric mean anti-A concen- (Table VI and Fig. 1 ). Tlhus, for examllple, the geometric mean aniti-A conlcenitrations after booster inmmunizatioln wvitlh 25 ,ug of A vaccine were 2.09 and 4.00 Mg/mil at 7 and 12 mo, respectively (Table VI) , significantly higher than the responses observed after primary injections at the same ages, 0.37 and 0.77 Mug/ml. Furtlhermore, the seroconversion rates after boosters were also higher than after primary immunization (compare Tables V and VII) although differences were statistically significant only at 7 mo (X2 = 6.784, P < 0.02). The magnitude of the booster response tended to increase with age, although the differences were not statistically significant.
No significant differences between responses to booster immunization with 25-or 100-Mg doses were observed at 7 mo of age either in terms of geometric mlean anti-A coiicenitiratio(T (Table VI) Table I ). All groups received lot A-5 except those given 10-and 100-jig boosters at 12 mo of age. These received lot A-7.
t No tested, number of infants from whom sera were available for testing. § GM (95% limits), geometric mean and 95% confidence limits of the mean. Not tested: the number of infants receiving booster immunizations of A vaccine from whom sera were not obtained or were insufficient for testing.
Persistence of anti-A response. The anti-A concentration of infants immunized at 3 mo of age was not significantly hiigher at 7 mo of age than that of unimmunized infants (Table IV) . 85% (23 out of 27) of the V Vaccine dose: dose of booster, which was the same as primary dose given at 3 mo of age, except for infants receiving 5 jig at 3 and 1C jig at 12 mo of age (see Table I ). All groups received lot A-5 except those receiving 5 jig at 3 and 10 jug at 12 mo of age. These received lot A-7. § No. tested, number of paired pre-aindl 1 mo p)ostilllluilization sera available for testing. 1 1 Seroconversion = Change from noidetectable anti-A cOslcentration (less than 0.13 jig/ml) before immunization to detectable concentration after immunization or a twofold rise in detectable anti-A concentration.
immunized infants had detectable anti-A at 12 mo of age, compared to 59% ( 16 out of 27) of those not previously immunized (x% = 4.53, P < 0.05). Fig. 2 illustrates the persistence of anti-A antibody levels after immunization of infants at 3 or 7 mo of age with 25 jig of A vaccine. The anti-A concentration of infants receiving primary immunization at 7 mo of age showed an insignificant decline, from the peak of 0.37 jug/ml to 0.31 jig/ml by 12 mo of age. The anti-A concentration of infants given boosters at 7 mo of age declined by more than 50% from peak values by 12 mo of age (from 2.09 to 1.25 Ag/ml), but this latter anti-A con- T Not tested, the number of infants receiving primary immunization with C vaccine from whom sera were not obtained or were insufficient in amount for testing. centration was still significantly higher than that of infants who had received primary immunization at 3 or 7 mo of age. No differences in persistence of anti-A levels were observed after doses of 25 or 100 Ag of A vaccine.
Antibody response to group C polysaccharide Aatutral acqutisition of antti-C. Only 9.6% of infants had detectable anti-C at 3 mo of age (geometric mean anti-C at least 0.10 Ag/ml). There was no significant increase in the percentage of infants with detectable anti-C nor in the geometric mean anti-C concentration between 3 and 12 mo of age (Table IX) .
Response to primnary immunization. There was an almost linear increase in the geometric mean anti-C concentration induced by primary immunization with C vaccine at 3, 7, and 12 mo of age (Table IX and Fig.  3 ). The seroconversion rates at 3, 7, and 12 mo of age are indicated in Table X Tables X and XII: 7 mo, x2 = 39.38, P < 0.001; 12 mo, x2 = 6.19, P < 0.02). This phenomenon is illustrated for the 25-lAg dose of C vaccine in Fig. 3 .
A notable exception to the depressed response after Rather the geometric mean anti-C concentrations after primary and booster immunizations at 7 mo of age with 10 ug were similar, 0.74 and 0.77 /Ag/ml, respectively (Tables IX and XI) , as were the seroconversion rates of 80 and 92%. (Tables X and XII) .
Correlation of anti-C concentration before and after immunization. There was no correlation between the presence or absence of detectable anti-C at 7 or 12 mo of age and the magnitude of the antibody response to primary or booster immunization with C vaccine. Persistence of anti-C response. The persistence of anti-C concentration of infants immunized with 25 ,ug of C vaccine is illustrated in Fig. 4 . Similar results were observed with doses of 100 lAg. The geometric mean anti-C concentration of infants immunized at 3 mo of age declined from a peak of 0.42 Ag/ml 1 mo after immunization to 0.17 lAglml b)y 7 mo and to 0.12 iLglml by 12 mo of age. Moreover, 69% (31 or 45) of the infants immunized at 3 mo of age had detectable anti-C at 12 mo of age, compared to only 21% (8 of 37) of the unimmunized infants (x9=18.88; P <0.001). The rate of decline of anti-C concentration from the postimmunization peak in infants receiving primary immunization at 7 mo of age was similar to that of infants immunized at 3 mo of age. There was no significant difference in the anti-C concentration at 12 mo of age between the infants who had received a single dose of C vaccine at 3 mo of age and those given two doses at 3 and 7 mo of age.
DISCUSSION
Results of preliminary studies of the groups A and C meningococcal polysaccharides in infants (15) have been confirmed by the present study. The antibody responses of infants to immunization with A and C vaccines depend on a number of factors including the age of the infant, the dose of antigen, the molecular weight of the antigen, the number of doses of antigen, and the prior experience of the infant with naturally occurring antigens cross-reactive with the meningococcal polysaccharides. Each of these factors will be discussed briefly.
Age. No response to A vaccine was detected in infants immunized at 3 mo of age. This lack of response was most likely due to the suppression of endogenous Not tested, number of infants receiiving booster immunizations of C vaccine from whom sera were not obtained or wNere insufficient in amount for testing.
antibody production by the high lev-els of miiaternal anti-A present in nmost inifants. The origin of the maternal anti-A is not likely the result of exposure to group A meniingococci, because suclh striainis lhav-e rarely been found in healtlhy carriers or in cases of mlleningococcal disease since the last major group A epidemiiic in the United States in 1945. The source of maternal anitigenic stimulus may be organisms witlh pol-sacclharide capsules cross-reactive Mwith group A meningococcal (12, 14) and into early adultlhood (20, 21 dependent relationship was seen with antibody production to the C vaccine in this and other studies (12, 15, 16) . Unlike the situation with the A vaccine, 3-mo-old infants had very low levels of maternal anti-C and produced a detectable antibody response to the C vaccine. Dose of antigen. Our results in infants confirm the observation in children and adults that 5 yg of C vaccine is inadequate and that 100 yg is superior to 25 Ag (14, 21 Further work is needed to determine the optimal dose of A vaccine in infancy.
Molecular weight of antigen. The immunogenicity of the A vaccine has been shown to be directly related to the average molecular weight of the polysaccharide. Gotschlich et al. found that lot A-5 (mol xvt 84,000) was more immunogenic than lot A-7 (mol wt 47,000) in adults and that the molecular weight of other lots of A vaccine was a major determinant of the response in infants and children (13) . In the present study, the difference in molecular weights of lots A-5 and A-7 may account for the significantly smaller response of 12- significant correlation with preimmunization levels of anti-A, suggesting that natural immunization had "primed" the immune system. Such priming is generally delayed with respect to the C polysaccharide until 2 yr of age, after which booster responses to the C vaccine occur. These findings are consistent with current immunological theory (22) , which suggests that "thymusindependent" antigens (e.g. high molecular weight polysaccharides) do not elicit true booster responses unless "memory" B-cells have first been formed as a result of cooperative interaction of T-cells (thymus-derived lymphocytes) and B-cells (antibody-forming cell precursors). Such T-and B-cell cooperation usually occurs in response to "thymus-dependent" antigens (e.g. proteinpolysaccharide complexes). Our hypothesis is, therefore, that naturally occurring antigens that cross-react with the A or C meningococcal antigens and that give rise to the age-related increases in naturally acquired anti-A and anti-C antibodies are thymus-dependent antigens, whereas the purified meningococcal polysaccharides are thymus-independent antigens.
The mechanism of natural immunization of infants to A polysaccharide remains to be determined. Enteric and genus Bacilluis organisms have been found with capsular polysaccharides immunochemically identical or very closely related to the capsular polysaccharide of serogroups A, B, and C meningococci (23) (24) (25) (26) . Differences in prevalence and age of acquisition of such organisms may be responsible for the observed differences in age of naturally acquired anti-A and anti-C antibodies.
Efficacy of meninigococcal vaccines. It remains to be determined whether the antibody levels achieved by infants in response to the meningococcal vaccines will be sufficient to protect them against meningococcal disease. Both naturally acquired and vaccine-induced antibody to the A and C vaccines have been shown to protect adults against disease (8, 9) . In addition, the A vaccine has been demonstrated to be 100% protective in Egyptian school children 6-15 yr of age, and such protection has lasted for at least 2 yr (10). The mol wt of the A vaccine used in Egypt was 170,000, approximately twice as large as lot A-5 (10) . While the minimal protective concentration of anti-A is not yet established, geometric mean anti-A concentrations of [9] [10] [11] [12] [13] [14] [15] Ag/ml were induced in the Eg-yptian children with a single dose of 50 ytg of vaccine. Similar anti-A concentrations have been achieved after primary immunization with lot A-5 of children over 2 yr of age in the United States (12, 14) . In the present study, anti-A concentrations of 2-4 Iug/ml were induced by booster immunization of 7-and 12-mo-old infants. A field trial to determine the efficacy of these levels of anti-A in protecting infants and young children against epidemic group A meningococcal disease is currently in progress in Finland. In addition, we are evaluating the antibody response of infants to three doses of A vaccine given sequentially at 2, 4, and 6 mo of age.
The C vaccine has been demonstrated to be 75% protective in Brazilian children 24-35 mo of age under epidemic conditions (9) . However, there was no protection apparent in infants 6-23 mo of age. Although the minimal protective level of anti-C has not yet been determined, the antibody responses of the Brazilian infants were considerably smaller than those of Danbury infants. Thus, it is possible that protective anti-C concentrations may be achieved at an earlier age in infants from white, middle-class American families. Nonetheless, it is clear that the presently available C vaccines are not likely to be protective in very young infants and that further research is required to learn how to enhance the anti-C response at these ages. This is not to say that the presently available vaccine is without merit, since it should be effective in controlling epidemics of serogroup C meningococcal disease, during which approximately 75% of cases occur in children more than 2 yr of age and in adults.2
